Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Cartesian Therapeutics, Inc. (RNAC : NSDQ)
 
 • Company Description   
Cartesian Therapeutics is a clinical-stage company pioneering RNA cell therapies for the treatment of autoimmune diseases. The company's lead asset, Descartes-08, is a potential first-in-class, RNA-engineered chimeric antigen receptor T-cell therapy in Phase 2b clinical development for patients with generalized myasthenia gravis. Cartesian Therapeutics, formerly known as Selecta Biosciences Inc., is based in WATERTOWN, Mass.

Number of Employees: 66

 
 • Price / Volume Information   
Yesterday's Closing Price: $9.68 Daily Weekly Monthly
20 Day Moving Average: 48,092 shares
Shares Outstanding: 26.00 (millions)
Market Capitalization: $251.70 (millions)
Beta: 0.39
52 Week High: $26.50
52 Week Low: $8.46
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -15.31% -16.80%
12 Week -3.20% -12.07%
Year To Date -45.95% -50.35%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
7495 New Horizon Way
-
Frederick,MD 21703
USA		 ph: 301-348-8698
fax: 617-924-3454		 megan.leduc@cartesiantx.com http://www.cartesiantherapeutics.com
 
 • General Corporate Information   
Officers
Carsten Brunn - President and Chief Executive Officer; and Directo
Blaine Davis - Chief Financial Officer
Carrie S. Cox - Director
Timothy C. Barabe - Director
Nishan de Silva - Director

Peer Information
Cartesian Therapeutics, Inc. (CORR.)
Cartesian Therapeutics, Inc. (RSPI)
Cartesian Therapeutics, Inc. (CGXP)
Cartesian Therapeutics, Inc. (BGEN)
Cartesian Therapeutics, Inc. (GTBP)
Cartesian Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 816212302
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 06/01/25
Next Expected EPS Date: 11/06/25
Share - Related Items
Shares Outstanding: 26.00
Most Recent Split Date: 4.00 (0.03:1)
Beta: 0.39
Market Capitalization: $251.70 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.81 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.11 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 11/06/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: 5.25
EPS Growth
vs. Year Ago Period: -7.41%
vs. Previous Quarter: 173.53%
Sales Growth
vs. Year Ago Period: -99.11%
vs. Previous Quarter: -72.91%
ROE
06/30/25 - -
03/31/25 - -
12/31/24 - -
ROA
06/30/25 - -6.36
03/31/25 - -7.01
12/31/24 - -5.58
Current Ratio
06/30/25 - 13.33
03/31/25 - 12.34
12/31/24 - 9.43
Quick Ratio
06/30/25 - 13.33
03/31/25 - 12.34
12/31/24 - 9.43
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -3,506.15
03/31/25 - -111.27
12/31/24 - -198.23
Book Value
06/30/25 - -0.10
03/31/25 - -0.84
12/31/24 - -0.27
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Capital
06/30/25 - -
03/31/25 - -
12/31/24 - -
 

Powered by Zacks Investment Research ©